Milton C. Ault, III net worth and biography

Milton Ault, III Biography and Net Worth

Major Shareholder of Alzamend Neuro

Milton C. (Todd) Ault III founded our company and has served as our Chairman of the Board since inception and as our Executive Chairman since November 2018. As of June 10, 2021, Mr. Ault serves as our Chairman Emeritus. Mr. Ault is a seasoned business professional and entrepreneur who has spent more than 27 years identifying value in various financial markets including equities, fixed income, commodities and real estate. In March 2017, Mr. Ault was appointed Executive Chairman of the Board of Ault Global, in December 2017, Mr. Ault was appointed Chief Executive Officer of Ault Global and, on January 12, 2021, Mr. Ault resumed his title of Executive Chairman. Mr. Ault has served as Chairman of Ault & Company, a holding company since December 2015, and as Chairman of Avalanche International Corp., a publicly traded company (“Avalanche”), since September 2014. Since January 2011, Mr. Ault has been the Vice President of Business Development for MCKEA Holdings, LLC, a family office. Mr. Ault has consulted with many publicly traded and privately held companies, which range from development stage to mature businesses, providing each of them the benefit of his diversified experience.

What is Milton C. Ault, III's net worth?: The estimated net worth of Milton C. Ault, III is at least $1.23 million as of October 7th, 2024. Mr. Ault, III owns 945,000 shares of Alzamend Neuro stock worth more than $1,228,500 as of November 22nd. This net worth evaluation does not reflect any other investments that Mr. Ault, III may own. Learn More about Milton C. Ault, III's net worth.
How do I contact Milton C. Ault, III?: The corporate mailing address for Mr. Ault, III and other Alzamend Neuro executives is , , . Alzamend Neuro can also be reached via phone at 844-722-6303. Learn More on Milton C. Ault, III's contact information.
Has Milton C. Ault, III been buying or selling shares of Alzamend Neuro?: Milton C. Ault, III has not been actively trading shares of Alzamend Neuro within the last three months. Most recently, on Tuesday, August 6th, Milton C. Ault III bought 75 shares of Alzamend Neuro stock. The stock was acquired at an average cost of $2.75 per share, with a total value of $206.25. Following the completion of the transaction, the director now directly owns 77,268 shares of the company's stock, valued at $212,487. Learn More on Milton C. Ault, III's trading history.
Who are Alzamend Neuro's active insiders?: Alzamend Neuro's insider roster includes Milton Ault III (Major Shareholder), Milton Ault, III (Major Shareholder), Milton Ault, III. (Major Shareholder), Mark Gustafson (Director), and L. Smith (Insider). Learn More on Alzamend Neuro's active insiders.
Are insiders buying or selling shares of Alzamend Neuro?: During the last year, Alzamend Neuro insiders bought shares 7 times. They purchased a total of 803 shares worth more than $7,024.05. The most recent insider tranaction occured on August, 6th when Director Milton C Ault III bought 75 shares worth more than $206.25. Insiders at Alzamend Neuro own 10.6% of the company. Learn More about insider trades at Alzamend Neuro.
Information on this page was last updated on 8/6/2024.

Milton C. Ault, III Insider Trading History at Alzamend Neuro

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/6/2024	Buy	75	$2.75	$206.25	77,268
7/31/2024	Buy	25	$3.74	$93.50	77,193
4/19/2024	Buy	100	$6.90	$690.00	77,169
4/1/2024	Buy	33	$9.10	$300.30	77,069
1/5/2024	Buy	500	$10.20	$5,100.00	76,836
12/26/2023	Buy	50	$9.00	$450.00	2,603
12/22/2023	Buy	20	$9.20	$184.00	16,686
5/24/2023	Buy	120	$88.50	$10,620.00	2,553
3/16/2023	Buy	26	$75.00	$1,950.00	73,700
2/15/2023	Buy	6	$90.00	$540.00	73,673
12/27/2022	Buy	6	$88.50	$531.00	73,646
11/18/2022	Buy	6	$193.50	$1,161.00	73,586
10/31/2022	Buy	40	$178.50	$7,140.00	67,351
10/12/2022	Buy	13	$184.50	$2,398.50	67,311
10/6/2022	Buy	6	$214.50	$1,287.00	67,297
9/29/2022	Buy	23	$178.50	$4,105.50	67,291
8/25/2022	Buy	32	$144.00	$4,608.00	66,717
8/22/2022	Buy	240	$145.50	$34,920.00	66,684
8/15/2022	Buy	93	$159.00	$14,787.00	66,344
8/3/2022	Buy	13	$142.50	$1,852.50	66,244
7/27/2022	Buy	38	$130.50	$4,959.00	66,231
7/22/2022	Buy	15	$136.50	$2,047.50	66,193
7/18/2022	Buy	66	$147.00	$9,702.00	66,177
6/29/2022	Buy	66	$132.00	$8,712.00	66,111
6/17/2022	Buy	66	$132.00	$8,712.00	66,044
6/14/2022	Buy	66	$127.50	$8,415.00	65,911
6/7/2022	Buy	13	$141.00	$1,833.00	65,791
6/2/2022	Buy	53	$144.00	$7,632.00	65,777
5/26/2022	Buy	66	$136.50	$9,009.00	65,644
5/24/2022	Buy	107	$133.50	$14,284.50	65,577
5/17/2022	Buy	159	$147.00	$23,373.00	65,437
5/12/2022	Buy	166	$127.50	$21,165.00	65,277
5/5/2022	Buy	666	$160.50	$106,893.00	2,166
4/26/2022	Buy	17,777	$225.00	$3,999,825.00	64,444
4/22/2022	Buy	500	$141.00	$70,500.00	1,500
4/11/2022	Buy	333	$169.50	$56,443.50	1,000
3/18/2022	Buy	666	$165.00	$109,890.00
2/24/2022	Buy	150	$172.50	$25,875.00
1/27/2022	Buy	16	$210.00	$3,360.00
1/24/2022	Buy	33	$193.50	$6,385.50
1/18/2022	Buy	46	$249.00	$11,454.00
1/14/2022	Buy	20	$268.50	$5,370.00
1/7/2022	Buy	20	$289.50	$5,790.00
1/5/2022	Buy	13	$297.00	$3,861.00
12/23/2021	Buy	10	$315.00	$3,150.00
12/20/2021	Buy	166	$316.50	$52,539.00
12/17/2021	Buy	86	$372.00	$31,992.00
11/30/2021	Buy	35	$340.50	$11,917.50
11/22/2021	Buy	100	$285.00	$28,500.00
11/8/2021	Buy	966	$385.50	$372,393.00
9/14/2021	Buy	33	$405.00	$13,365.00	1,000
8/27/2021	Buy	40	$435.00	$17,400.00
8/17/2021	Buy	26	$493.50	$12,831.00
8/12/2021	Buy	22	$580.50	$12,771.00
8/9/2021	Buy	3	$607.50	$1,822.50
8/6/2021	Buy	26	$610.50	$15,873.00
8/4/2021	Buy	3	$645.00	$1,935.00
8/2/2021	Buy	10	$684.00	$6,840.00
7/30/2021	Buy	8,922	$226.50	$2,020,833.00
7/26/2021	Buy	23	$741.00	$17,043.00
7/23/2021	Buy	33	$864.00	$28,512.00
7/19/2021	Buy	26	$811.50	$21,099.00
7/16/2021	Buy	4	$934.50	$3,738.00
7/14/2021	Buy	33	$1,011.00	$33,363.00
7/12/2021	Buy	54	$922.50	$49,815.00
7/8/2021	Buy	13	$912.00	$11,856.00
7/6/2021	Buy	46	$1,060.50	$48,783.00
6/28/2021	Buy	60	$1,441.50	$86,490.00
6/25/2021	Buy	93	$1,318.50	$122,620.50
6/22/2021	Buy	493	$1,393.50	$686,995.50

Milton C. Ault, III Buying and Selling Activity at Alzamend Neuro

Alzamend Neuro Company Overview

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Today's Range

Now: $1.30

$1.27

$1.32

50 Day Range

MA: $1.60

$1.30

$1.93

2 Week Range

Now: $1.30

$1.25

$15.06

Volume

132,012 shs

Average Volume

510,774 shs

Market Capitalization

$5.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Central Bank Abandons USD

From Desko Digital | Ad

You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD!

Get Your FREE Gold Investor Kit NOW!

Milton Ault, III Biography and Net Worth

What is Milton C. Ault, III's net worth?

How do I contact Milton C. Ault, III?

Has Milton C. Ault, III been buying or selling shares of Alzamend Neuro?

Who are Alzamend Neuro's active insiders?

Are insiders buying or selling shares of Alzamend Neuro?

Milton C. Ault, III Insider Trading History at Alzamend Neuro

Milton C. Ault, III Buying and Selling Activity at Alzamend Neuro

Alzamend Neuro Company Overview

Today's Range

50 Day Range

2 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta